Zentek, Triera Biosciences receive $1.1M Government of Canada contract

Zentek (ZTEK) announces that its wholly-owned subsidiary Triera Biosciences has received a $1.1 million Government of Canada contract to test its multivalent aptamer technology for the rapid drug discovery of therapeutics or prophylactics of highly pathogenic avian influenza A. Highlights: The Government of Canada has identified the life sciences sector as a priority of the Canadian economy and is seeking advanced medical technology solutions to address ongoing challenges Triera was awarded a $1.1 million Government of Canada R&D contract through Innovation, Science and Economic Development Canada’s Innovative Solutions Canada program: Health Advanced And Emerging Medical Technologies Triera’s multivalent aptamer technology was selected for its potential to be used as a rapid drug development platform Government of Canada testing partners include Health Emergency Readiness Canada within ISED, and Defence Research and Development Canada, the science and technology organization of the Department of National Defence. The test will help develop a prophylactic and therapeutic for HPAI A following the multivalent aptamer strategy that successfully produced a SARS-CoV-2 aptamer.